INTRODUCTION
============

Diabetes is one of the most important and prevalent diseases in current society, with approximately 415 million people affected worldwide in 2015 and an estimate for the year 2040 of 642 million people \[[@B1]\]. Given the importance of this detail, one of the consequences of this disease must be highlighted, which is the diabetic foot, defined by the WHO (World Health Organization) as "the presence of ulceration, infection and/or gangrene in the foot associated with diabetic neuropathy and different degrees of peripheral vascular disease as a consequence of the complex interaction of different factors induced by maintained hyperglycemia" \[[@B2]\].

One of the most frequent problems among the patients who suffer from this condition is neuropathic pain, which in scientific terminology is known as painful diabetic neuropathy. It was defined by Boulton et al. (2005) \[[@B3]\] as the "presence of symptoms and/or signs of peripheral nervous dysfunction in people with diabetes, after excluding other causes".

Painful diabetic neuropathy is treated through numerous therapeutic alternatives. The most common therapies are based on antidepressants, anticonvulsants, antipsychotics, opioids, local anesthetics and inhibitors of serotonin and noradrenaline reuptake, among others. In addition to these drugs, most of which are administered orally, there are other ways of application, also commonly used, such as patches or creams, as well as non-pharmacological treatments, as is the case of physical therapies \[[@B4][@B5][@B6][@B7][@B8]\].

All of the abovementioned motivated the realization of the present study, which analyzed, as a meta-analysis, different treatments used to alleviate painful diabetic neuropathy, with the aim of generating results that help making decisions when applying such treatments to tackle this pathology.

MATERIALS AND METHODS
=====================

This meta-analysis was conducted following the "Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA)" guidelines \[[@B9]\].

1. Data sources
---------------

To obtain the data, a search in the main databases for Health Sciences, such as PUBMED, Web of Science (WOS) and IME biomedicina (Spanish Medical Reports in Biomedicine) was conducted, using the combination of the terms "pain", "painful diabetic neuropathy", "diabetic neuropathy", "neuropathic pain", "treatment", "therapy", "dolor neuropático", "dolor", "neuropatía diabética", "neuropatía diabética dolorosa", "tratamiento" and "terapia" through the boolean operators AND and OR, and the use of truncations.

Example of full electronic search strategy for a database.

PUBMED: "Painful diabetic neuropathy" AND (treatment OR therap^\*^)

All the resulting articles, regardless of their publication date, were susceptible of inclusion in the study, until the final date of the search.

2. Selection of studies
-----------------------

All those randomized controlled trials that were accessible in full-text and met the inclusion criteria according to the PICO process (P: patient; I: intervention; C: comparison; O: outcomes) were included.

1\. Patients: Patients over 18 years of age, diabetic, and with neuropathic pain.

2\. Intervention: Application of physical, topical or oral therapy for the treatment of painful diabetic neuropathy.

3\. Comparison: Randomized clinical trials compared with a control group.

4\. Outcomes: Measuring of the initial and final pain according to the corresponding scale.

The authors excluded those articles that lacked the pain assessment scale, the demographic characteristics of the sample and the data of the statistical analyses performed that would be necessary for the later realization of the meta-analysis.

3. Data extraction
------------------

Surveys were carried out to collect the data of the potentially eligible studies. They gathered the data about the sample size, the type of intervention performed and dosage, the comparison conducted, the results obtained related to the measurement of initial and final pain (with standard deviation), the pain scale used, the duration of the diabetes, the duration of the neuropathic pain, the follow up time of the patients and reference. This extraction was performed by the main author of the present study and an external collaborator. In the absence of indispensable data for the realization of the meta-analysis, the authors of those studies involved were contacted and asked for this information. In all the cases in which the authors were contacted (via e-mail), there was either no reply or the e-mail address provided in the article did no longer exist.

4. Measures of quality and risk of bias for the studies
-------------------------------------------------------

As a quality measure, the Jadad scale was used. This scale described by Jadad et al. (1996) \[[@B10]\] is an instrument that measures the methodological quality of randomized trials in pain research, thus the authors of the present study consider it essential to apply it in the studies selected. The scale was applied to these articles, excluding those that did not obtain a score of 3 or higher.

As a risk of bias assessment, the articles that were not excluded were screened using the tool provided by the Cochrane Collaboration. This tool is based on domains like random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. According to these domains, each study can be classified as high risk, low risk and unclear risk \[[@B11][@B12]\].

Both the Jadad scale and the Cochrane Collaboration tool for risk of bias assessment were applied in parallel by the main author and an external collaborator. Similar results were obtained from both researchers.

5. Statistical analysis
-----------------------

For the analysis and interpretation of the data of the studies selected, the mean value of the final pain and the effect size of each of the studies were calculated, as measurements of central tendency and dispersion. The standard deviation is the statistical element that takes into account both components, which allows to properly weight each study included in the meta-analysis; therefore, it was considered as inclusion criterion that each study had the mean value and the standard deviation for final pain both in the experimental group and in the placebo group.

The effect size was calculated for each of the articles selected, as well as the global effect size for each of the treatment types. Hedge\'s g is a standardized measurement of the effect size that allows to compare assessments performed with different tests and scales. This measurement of the effect size does not indicate how many standard deviations the effect has. The interpretation of this measure is based on the g value in absolute value, specifically:

1\. absolute g value 0--0.2: no effect

2\. absolute g value 0.2--0.5: small effect

3\. absolute g value 0.5--0.8: medium effect

4\. absolute g value \> 0.8: large effect

A forest plot was used for the graphical representation of the confidence intervals of the values of the effect size. It was interpreted in a way that negative values indicate pain improvement. All those confidence intervals that included zero were not considered significant in the improvement of pain.

RESULTS
=======

1. Search results
-----------------

From the initial search in the different databases, 997 articles were obtained for analysis, of which 9 were eventually included after applying the inclusion criteria and analyzing them in detail ([Fig. 1](#F1){ref-type="fig"}).

These 9 articles include topical therapies (clonidine and capsaicin), physical therapies through two types of magnetotherapy, and oral pharmacological therapies such as gabapentin, pregabalin, duloxetine, topiramate and tapentadol. The characteristics of the studies are shown in [Table 1](#T1){ref-type="table"} \[[@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21]\].

2. Risk of bias and quality measures
------------------------------------

Of the articles analyzed using the Cochrane Collaboration tool, "low risk" was obtained in a large percentage of them, with two studies showing this in all their domains. In two other articles there was "high risk" in the domain "Blinding of participants and personnel" due to the lack of blinding throughout the study, since it does not mention whether or not it was performed ([Fig. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

With respect to the Jadad scale for the measurement of the methodological quality of randomized clinical trials, values over 3 points were obtained in all the articles analyzed, as can be seen in [Table 1](#T1){ref-type="table"}.

3. Meta-analytical results
--------------------------

Regarding the types of therapy included in the meta-analysis, two therapies showed no effect, which were the physical therapy \[g: −0.052, 95% CI (−0.229; 0.194)\] and the topical therapy \[g: −0.238, 95 % CI (−0.524; 0.047)\]. The oral therapy obtained a small effect size \[g: −0.266, 95% CI (−0.357; −0.175)\].

With respect to the individual results of the studies analyzed about the level of final pain, there were two studies with a large effect size, wich are Goldstein et al. \[[@B13]\] about duloxetine at 20 mg/day \[g: −1.622, 95% CI (−1.650; −1.594), *P* \< 0.05\] and Niesters et al. \[[@B14]\] about tapentadol \[g:−1.333, 95% CI (−1.594; −1.072), *P* \< 0.05\]. The study by Richter et al. \[[@B15]\] about pregabalin at 600 mg/day \[g: −0.607, 95% CI (−0.980; −0.325), *P* \< 0.05\] showed a medium effect size. The studies with a small effect size were those by Richter et al. \[[@B15]\] about pregabalin at 150 mg/day (g: −0.407, 95% CI \[−0.744; −0.070\] *P* \< 0.05\] and Campbell et al. \[[@B16]\] about clonidine \[g: −0.242, 95 % CI (−0.543; −0.058), *P* \< 0.05\] ([Fig. 4](#F4){ref-type="fig"}).

DISCUSSION
==========

The main purpose of this meta-analysis was to determine the level of effectiveness of the treatments included in nine clinical trials analyzed. The results obtained through this study indicate that the clinical trials by Richter et al. \[[@B15]\], Niesters et al. \[[@B14]\], Campbell et al. \[[@B16]\], and Goldstein et al. \[[@B13]\] (in the latter case the dose analyzed was 20 mg/day, since the rest of the doses did not have statistical viability) had a larger effect size regarding the assessment of the final pain of the patients.

These treatments are present in different clinical practice guidelines and recommendations for neuropathic pain, of which the most cited in the literature are those of the American Academy of Neurology (AAN) \[[@B7]\], the National Institute for Health and Care Excellence (NICE) \[[@B22]\], the European Federation of Neurological Societies (EFNS) \[[@B4]\] and the Neuropathic Pain Special Interest Group of International Association for the Study of Pain (NEUPSIG) \[[@B23]\].

The present study shows a high efficiency for the treatments based on gabapentin, duloxetine and pregabalin, which is in line with the aforementioned guidelines, in which they are categorized as first-level drugs for the treatment of painful diabetic neuropathy. In the case of gabapentin, in spite of being a study without effect according to the meta-analysis performed, it can be asserted that the results are positive regarding pain relief in the patients studied, especially at doses of 3600 mg/day.

Two other studies with positive results are those that tackled pain using tapentadol and clonidine. In the case of tapentadol, the results of the present study confirm that it is a useful drug for the treatment of painful diabetic neuropathy; however, the recommendations of the guidelines of the ENS and the NEUPSIG indicate that its use is better prescribed for painful processes in acute stages and short periods.

Of the rest of the oral or topical pharmacological therapies, it is worth mentioning that, although they were studies that did not obtain satisfactory results according to the meta-analysis conducted, they did show benefits related to pain relief.

A special case is that of physical therapies, which do not show satisfactory results, and are not valued or described in the recommendation guides, or they are not even recommended by the AAN \[[@B7]\].

The authors found as a limitation the absence of reply from the authors of different articles when contacting them to request more statistical data that would allow them to be included in the meta-analysis.

In conclusion, this meta-analysis indicates the effectiveness of the treatments based on duloxetine, gabapentin and pregabalin. Other drugs, such as tapentadol and topical clonidine, also obtained good results, although the use of the former may be limited to more specific situations. The physical therapies analyzed did not show any type of benefit for diabetic patients with neuropathic pain.

The present study followed a very strict methodology in the analysis and selection of clinical trials. Thereby, despite the fact that it was not possible to include a large number of studies, the results provided can help increase the knowledge about the treatment of painful diabetic neuropathy and the development of clinical practice guidelines for healthcare professionals.
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###### Characteristics of the Studies Analyzed
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GAB: Gabapentin, PRE: Pregabalin, PEMF: Pulsed Electromagnetic Fields.
